ZRC 3308
Alternative Names: ZRC-3308Latest Information Update: 04 Jun 2021
Price :
$50 *
At a glance
- Originator Zydus Cadila
- Class Antivirals; Monoclonal antibodies
- Mechanism of Action Virus internalisation inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical COVID 2019 infections
Most Recent Events
- 27 May 2021 Preclinical trials in COVID-2019 infections in India (Parenteral) before May 2021
- 27 May 2021 Zydus Cadila announces intention to submit clinical trial application to Drugs Controller General of India (DCGI) for COVID-2019 infections
- 27 May 2021 Pharmacodynamics data from a preclinical studies inCOVID-2019 infections released by Zydus Cadila